
What smart money is saying about DexCom, Inc.
5 funds in our archive have pitched DexCom, Inc. — most recently Alpha Wealth Funds in March 2026.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Fund coverage · 5 theses
- Alpha Wealth FundsMarch 2026
DexCom is a leading CGM company targeting large Type 2 diabetes expansion and Medicare coverage for significant long-term growth.
Read the full thesis - Aristotle Large Cap GrowthDecember 2025
DexCom is a leading CGM company with low market penetration, strong reimbursement, and new products supporting sustained double-digit growth and a justified premium.
Read the full thesis - Aristotle Focus GrowthDecember 2025
DexCom is a CGM leader with favorable reimbursement, product innovation, and large untapped markets supporting sustained growth at a justified premium valuation.
Read the full thesis - Aristotle Core EquitySeptember 2025
Dexcom is a strong investment opportunity in the medical device sector, specializing in continuous glucose monitoring systems with significant growth potential and a solid financial foundation.
Read the full thesis - Bell Global Equities FundAugust 2025
Dexcom is a fast-growing US MedTech company specializing in continuous glucose monitoring systems, poised for significant growth due to its strong market position and expanding opportunities in type 2 diabetes management.
Read the full thesis
Read every full thesis on DexCom, Inc.
Unlock all 5 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→